Biology of testicular germ cell tumors

References

• Looijenga LH, Oosterhuis JW. Pathogenesis of testicular germ cell tumours. Rev. Reprod.4, 90–100 (1999).
   PubMedGoogle Scholar
• Einhorn LH. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol.8, 1777–1781 (1990).
   PubMed Web of Science ®Google Scholar
• Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J. Urol.170, 5–11 (2003).
   PubMed Web of Science ®Google Scholar
• Adami HO, Bergström R, Möhner M et al. Testicular cancer in nine northern European countries. Int. J. Cancer59, 33–38 (1994).
   PubMed Web of Science ®Google Scholar
• Bergström R, Adami HO, Möhner M et al. Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J. Natl Cancer Inst.88, 727–733 (1996).
   PubMed Web of Science ®Google Scholar
• Moul JW, Schanne FJ, Thompson IM et al. Testicular cancer in blacks: a multicenter experience. Cancer73, 388–393 (1994).
   PubMed Web of Science ®Google Scholar
• Richiardi L, Pettersson A, Akre O. Genetic and environmental risk factors for testicular cancer. Int. J. Androl.30, 230–241 (2007).
   PubMedGoogle Scholar
• Hemminki K, Li X. Cancer risks in Nordic immigrants and their offspring in Sweden. Eur. J. Cancer38, 2428–2434 (2002).
   PubMedGoogle Scholar
• Ekbom A, Richiardi L, Akre O, Montgomery SM, Sparén P. Age at immigration and duration of stay in relation to risk for testicular cancer among Finnish immigrants in Sweden. J. Natl Cancer Inst.95, 1238–1240 (2003).
   PubMedGoogle Scholar
• Hemminki K, Li X. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br. J. Cancer90, 1765–1770 (2004).
   PubMed Web of Science ®Google Scholar
• Heimdal K, Olsson H, Tretli S, Flodgren P, Børresen AL, Fossa SD. Familial testicular cancer in Norway and southern Sweden. Br. J. Cancer73, 964–969 (1996).
   PubMed Web of Science ®Google Scholar
• Forman D, Oliver RT, Brett AR et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br. J. Cancer65, 255–262 (1992).
   PubMed Web of Science ®Google Scholar
• Wanderås EH, Fosså SD, Tretli S. Risk of second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. Eur. J. Cancer33, 244–252 (1997).
   PubMedGoogle Scholar
• Osterlind A, Berthelsen JG, Abildgaard N et al. Risk of bilateral testicular germ cell cancer in Denmark: 1960–1984. J. Natl Cancer Inst.83, 1391–1395 (1991).
   PubMed Web of Science ®Google Scholar
• United Kingdom Testicular Cancer Study Group. Aetiology of testicular cancer: association with congenital abnormalities, age at puberty, infertility, and exercise. BMJ308, 1393–1399 (1994).
   PubMed Web of Science ®Google Scholar
• Pottern LM, Brown LM, Hoover RN et al. Testicular cancer risk among young men: role of cryptorchidism and inguinal hernia. J. Natl Cancer Inst.74, 377–381 (1985).
   PubMedGoogle Scholar
• Pettersson A, Richiardi L, Nordenskjold A et al. Age at surgery for undescended testis and risk of testicular cancer. N. Engl. J. Med.356, 1835–1841 (2007).
   PubMedGoogle Scholar
• Nichols CR, Heerema NA, Palmer C et al. Klinefelter’s syndrome associated with mediastinal germ cell neoplasms. J. Clin. Oncol.5, 1290–1294 (1987).
   PubMed Web of Science ®Google Scholar
• Levin HS. Tumors of the testis in intersex syndromes. Urol. Clin. North Am.27, 543–551 (2000).
   PubMed Web of Science ®Google Scholar
• Satgé D, Sasco AJ, Curé H et al. An excess of testicular germ cell tumors in Down’s syndrome: three cases and a review of the literature. Cancer80, 929–935 (1997).
   PubMed Web of Science ®Google Scholar
• Skakkebaek NE. Possible carcinoma-in situ of the testis. Lancet2, 516–517 (1972).
   PubMed Web of Science ®Google Scholar
• Skakkebaek NE. Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. Histopathology2, 157–170 (1978).
   PubMed Web of Science ®Google Scholar
• Jacobsen GK, Henriksen OB, von der Maase H. Carcinoma in situ of testicular tissue adjacent to malignant germ cell tumors: a study of 105 cases. Cancer47, 2660–2662 (1981).
   PubMedGoogle Scholar
• Skakkebaek NE, Berthelsen JG, Giwercman A, Müller J. Carcinoma-in situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int. J. Androl.10, 19–28 (1987).
   PubMed Web of Science ®Google Scholar
• Nielsen H, Nielsen M, Skakkebaek NE. The fine structure of possible carcinoma-in situ in the seminiferous tubules in the testes of four infertile men. Acta Pathol. Microbiol. Scand. A82, 235–248 (1974).
   PubMedGoogle Scholar
• Rajpert-De Meyts E, Bartkova J, Samson M et al. The emerging phenotype of the testicular carcinoma in situ germ cell. APMIS111, 267–278 (2003).
   PubMedGoogle Scholar
• Koide O, Iwai S, Baba K, Iri H. Identification of testicular atypical germ cells by an immunohistochemical technique for placental alkaline phosphatase. Cancer60, 1325–1330 (1987).
   PubMed Web of Science ®Google Scholar
• Giwercman A, Cantell L, Marks A. Placental-like alkaline phosphatase as a marker of carcinoma in situ of the testis. Comparison with monoclonal antibodies M2A and 43–9F. APMIS99, 586–594 (1991).
   PubMedGoogle Scholar
• Jorgensen N, Rajpert-De Meyts E, Graem N, Müller J, Giwercman A, Skakkebaek NE. Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. Lab. Invest.72, 223–231 (1995).
   PubMed Web of Science ®Google Scholar
• Rajpert-De Meyts E, Hanstein R, Jorgensen N, Graem N, Vogt PH, Skakkebaek NE. Developmental expression of POU5F1 (OCT3/4) in normal and dysgenetic human gonads. Hum. Reprod.19, 1338–1344 (2004).
   PubMed Web of Science ®Google Scholar
• Hoei-Hansen CE, Nielsen JE, Almstrup K et al. Transcription factor AP-2γ is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin. Cancer Res.10, 8521–8530 (2004).
   PubMedGoogle Scholar
• van Gurp RJ, Oosterhuis JW, Kalscheuer V, Mariman EC, Looijenga LH. Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. J. Natl Cancer Inst.86, 1070–1075 (1994).
   PubMedGoogle Scholar
• Hoei-Hansen CE, Nielsen JE, Almstrup K et al. Identification of genes differentially expressed in testes containing carcinoma in situ. Mol. Hum. Reprod.10, 423–431 (2004).
   PubMedGoogle Scholar
• Almstrup K, Hoei-Hansen CE, Wirkner U et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res.64, 4736–4743 (2004).
   PubMed Web of Science ®Google Scholar
• Skotheim RI, Lind GE, Monni O et al. Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res.65, 5588–5598 (2005)
   PubMed Web of Science ®Google Scholar
• Almstrup K, Leffers H, Lothe RA et al. Improved gene expression signature of testicular carcinoma in situ. Int. J. Androl.30, 292–303 (2007).
   PubMedGoogle Scholar
• Rajpert-De Meyts E, Jørgensen N, Brøndum-Nielsen K, Müller J, Skakkebaek NE. Developmental arrest of germ cells in the pathogenesis of germ cell neoplasia. APMIS106, 198–204 (1998).
   PubMedGoogle Scholar
• Rajpert-De Meyts E, Skakkebaek NE. The possible role of sex hormones in the development of testicular cancer. Eur. Urol.23, 54–59 (1993).
   PubMedGoogle Scholar
• Chaganti RSK, Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res.60, 1475–1482 (2000).
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int. J. Cancer83, 815–822 (1999).
   PubMed Web of Science ®Google Scholar
• Von der Maase H, Rørth M, Walbom?Jørgensen S et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br. Med. J.293, 1398–1401 (1986).
   PubMed Web of Science ®Google Scholar
• Giwercman A, von der Maase H, Berthelsen JG, Rørth M, Bertelsen A, Skakkebaek NE. Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J. Clin. Endocrinol. Metab.73, 596–603 (1991).
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Besserer A, Loy V. Low-dose radiation therapy of testicular intraepithelial neoplasia. J. Cancer Res. Clin. Oncol.119, 355–359 (1993).
   PubMedGoogle Scholar
• Giwercman A, Berthelsen JG, Müller J, von der Maase H, Skakkebaek NE. Screening for carcinoma-in situ of the testis. Int. J. Androl.10, 173–180 (1987).
   PubMedGoogle Scholar
• Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann. Oncol.16, 863–868 (2005).
   PubMed Web of Science ®Google Scholar
• Daugaard G, Giwercman S, Skakkebaek NE. Should the other testis be biopsied? Semin. Urol. Oncol.14, 8–12 (1996).
   PubMedGoogle Scholar
• Dieckmann KP, Loy V. Prevalence of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell neoplasms. J. Clin. Oncol.14, 3126–3132 (1996).
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Loy V. The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience. APMIS106, 13–20 (1998).
   PubMedGoogle Scholar
• Dieckmann KP, Loy V. Management of contralateral testicular intraepithelial neoplasia in patients with testicular germ-cell tumor. World J. Urol.12, 131–135 (1994).
   PubMedGoogle Scholar
• Heidenreich A, Moul JW. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Semin. Urol. Oncol.20, 234–238 (2002).
   PubMedGoogle Scholar
• Jones RH, Vasey PA. Part I: testicular cancer – management of early disease. Lancet Oncol.4, 730–737 (2003).
   PubMedGoogle Scholar
• Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur. Urol.53, 478–496 (2008).
   PubMed Web of Science ®Google Scholar
• Herr HW, Sheinfeld J. Is biopsy of the contralateral testis necessary in patients with germ cell tumors? J. Urol.158, 1331–1334 (1997).
   PubMed Web of Science ®Google Scholar
• Fosså SD, Chen J, Schonfeld SJ et al. Risk of contralateral testicular cancer: a population-based study of 29515 U.S. men. J. Natl Cancer Inst.97, 1056–1066 (2005).
   PubMed Web of Science ®Google Scholar
• de Gouveia Brazao CA, Pierik FH, Oosterhuis JW, Dohle GR, Looijenga LH, Weber RF. Bilateral testicular microlithiasis predicts the presence of the precursor of testicular germ cell tumors in subfertile men. J. Urol.171, 158–160 (2004).
   PubMedGoogle Scholar
• Harland SJ, Rapley EA, Nicholson PW. Do all patients with bilateral testis cancer have a hereditary predisposition? Int. J. Androl.30, 251–255 (2007).
   PubMedGoogle Scholar
• Swerdlow AJ, De Stavola BL, Swanwick MA, Maconochie NES. Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology. Lancet350, 1723–1728 (1997).
   PubMed Web of Science ®Google Scholar
• Hemminki K, Chen B. Are twins at risk of cancer: results from the Swedish family-cancer database. Twin Res. Hum. Genet.8, 509–514 (2005).
   PubMedGoogle Scholar
• Lutke Holzik MF, Rapley EA, Hoekstra HJ, Sleijfer DT, Nolte IM, Sijmons RH. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol.5, 363–371 (2004).
   PubMed Web of Science ®Google Scholar
• The International Testicular Cancer Linkage Consortium. Candidate regions for testicular cancer susceptibility genes. APMIS106, 64–70 (1998).
   PubMedGoogle Scholar
• Crockford GP, Linger R, Hockley S et al. Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum. Mol. Genet.15, 443–451 (2006).
   PubMedGoogle Scholar
• Oosterhuis JW, Castedo SM, de Jong B et al. Ploidy of primary germ cell tumors of the testis. Pathogenetic and clinical relevance. Lab. Invest.60, 14–21 (1989).
   PubMed Web of Science ®Google Scholar
• El-Naggar AK, Ro JY, McLemore D, Ayala AG, Batsakis JG. DNA ploidy in testicular germ cell neoplasms. Histogenetic and clinical implications. Am. J. Surg. Pathol.16, 611–618 (1992).
   PubMedGoogle Scholar
• De Graaf WE, Oosterhuis JW, de Jong B et al. Ploidy of testicular carcinoma in situ. Lab. Invest.66, 166–168 (1992).
   PubMedGoogle Scholar
• Atkin NB, Baker MC. Specific chromosome change, i(12p), in testicular tumours? Lancet11, 1349 (1982).
   Google Scholar
• Suijkerbuijk RF,Sinke RJ, Meloni AM et al. Overrepresentation of chromosome 12p sequences and karyotypic evolution in i(12p)-negative testicular germ-cell tumors revealed by fluorescence in situ hybridization. Cancer Genet. Cytogenet.70, 85–93 (1993).
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Houldsworth J, Reuter VE et al. Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. Genes Chromosomes Cancer8, 230–236 (1993).
   PubMedGoogle Scholar
• Mostert MMC, van de Pol M, Olde Weghuis D et al. Comparative genomic hybridization of germ cell tumors of the adult testis: confirmation of karyotypic findings and identification of a 12p amplicon. Cancer Genet. Cytogenet.89, 146–152 (1996).
   PubMedGoogle Scholar
• Korn MW, Olde Weghuis DEM, Suijkerbuijk RF et al. Detection of chromosomal DNA gains and losses in testicular germ cell tumors by comparative genomic hybridization. Genes Chromosomes Cancer17, 78–87 (1996).
   PubMed Web of Science ®Google Scholar
• Suijkerbuijk RF, Sinke RJ, Olde Weghuis DEM et al. Amplification of chromosome subregion 12p11.2–12.1 in a metastasis of an i(12p)-negative seminoma: relationship to tumor progression? Cancer Genet. Cytogenet.78, 145–152 (1994).
   PubMedGoogle Scholar
• Mostert MC, Verkerk AJMH, van de Pol M et al. Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. Oncogene16, 2617–2627 (1998).
   PubMed Web of Science ®Google Scholar
• Roelofs H, Mostert MC, Pompe K et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am. J. Pathol.57, 1155–1166 (2000).
   Google Scholar
• Kraggerud SM, Skotheim RI, Szymanska J et al. Genome profiles of familial/bilateral and sporadic testicular germ cell tumors. Genes Chromosomes Cancer34, 168–174 (2002).
   PubMedGoogle Scholar
• Henegariu O, Heerema NA, Thurston V, Jung SH, Pera M, Vance GH. Characterization of gains, losses, and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization. Cancer Genet. Cytogenet.148, 14–20 (2004).
   PubMedGoogle Scholar
• Houldsorth J, Reuter V, Bosl GJ, Chaganti RSK. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis.Cell Growth Differ.8, 293–299 (1997).
   PubMedGoogle Scholar
• Zafarana G, Gillis AJM, van Gurp RJHLM et al. Coamplification of DAD-R, SOX5 and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res.62, 1822–1831 (2002).
   PubMedGoogle Scholar
• Rodriguez S, Jafer O, Goker H et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p1.2–p12.1. Oncogene22, 1880–1891 (2003).
   PubMedGoogle Scholar
• Bourdon V, Naef F, Rao PH et al. Genomic and expression analysis of the 12p11–p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. Cancer Res.62, 6218–6223 (2002).
   PubMedGoogle Scholar
• Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer104, 2255–2265 (2005).
   PubMed Web of Science ®Google Scholar
• Korkola JE, Houldsworth J, Chadalavada RSV et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res.66, 820–827 (2006).
   PubMed Web of Science ®Google Scholar
• Vos A, Oosterhuis J, de Jong B, Buist J, Schraffordt Koops H. Cytogenetics of carcinoma in situ of the testis. Cancer Genet. Cytogenet.46, 75–81 (1990).
   PubMedGoogle Scholar
• van Echten J, van Gurp RJHLM, Stoepker M, Looijenga LHJ, de Jong B, Oosterhuis JW. Cytogenetic evidence that carcinoma in situ is the precursor lesion for invasive testicular germ cell tumors. Cancer Genet. Cytogenet.85, 133–137 (1995).
   PubMedGoogle Scholar
• Geurts van Kessel A, van Drunen E, de Jong B, Oosterhuis JW, Langeveld A, Mulder MP. Chromosome 12q heterozygosity is retained in i(12p)-positive testicular germ cell tumor cells. Cancer Genet. Cytogenet.40, 129–134 (1989).
   PubMedGoogle Scholar
• Looijenga LHJ, Rosenberg C, van Gurp RJHLM et al. Comparative genomic hybridization of microdissected samples from different stages in the development of a seminoma and a non-seminoma. J. Pathol.191, 187–192 (2000).
   PubMedGoogle Scholar
• Rosenberg C, van Gurp RJHLM, Geelen E, Oosterhuis JW, Looijenga LHJ. Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. Oncogene19, 5858–5862 (2000).
   PubMedGoogle Scholar
• Summersgill B, Osin P, Lu YJ, Huddart R, Shipley J. Chromosomal imbalances associated with carcinoma in situ and associated testicular germ cell tumours of adolescents and adults. Br. J. Cancer85, 213–219 (2001).
   PubMed Web of Science ®Google Scholar
• Ottesen AM, Skakkebaek NE, Lundsteen C, Leffers H, Larsen J, Rajpert-De Meyts E. High-resolution comparative genomic hybridization detects extra chromosome arm 12p material in most cases of carcinoma in situ adjacent to overt germ cell tumors, but not before the invasive tumor development. Genes Chromosomes Cancer38, 117–125 (2003).
   PubMed Web of Science ®Google Scholar
• Skotheim RI, Monni O, Mousses S et al. New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res.62, 2359–2364 (2002).
   PubMed Web of Science ®Google Scholar
• McIntyre A, Summersgill B, Jafar O et al. Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene23, 9142–9147 (2004).
   PubMedGoogle Scholar
• Skotheim RI, Autio R, Lind GE et al. Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression change. Cell Oncol.28, 315–326 (2006).
   PubMedGoogle Scholar
• Bignell G, Smith R, Hunter C et al. Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer45, 42–46 (2006).
   PubMedGoogle Scholar
• Peng HQ, Hogg D, Malkin D et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res.53, 3574–3578 (1993).
   PubMed Web of Science ®Google Scholar
• Heimdal K, Lothe RA, Lystad S, Holm R, Fosså SD, Børresen AL. No germline TP53 mutations detected in familial and bilateral testicular cancer. Genes Chromosomes Cancer6, 92–97 (1993).
   PubMedGoogle Scholar
• Hatta Y, Hirama T, Takeuchi S et al. Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies. J. Urol.154, 1954–1957 (1995).
   PubMedGoogle Scholar
• Mauduit C, Hamamah S, Benahmed M. Stem cell factor/c-kit system in spermatogenesis. Hum. Reprod. Update5, 535–545 (1999).
   PubMed Web of Science ®Google Scholar
• Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am. J. Pathol.154, 1643–1647 (1999).
   PubMed Web of Science ®Google Scholar
• Kemmer K, Corless CL, Fletcher JA et al. KIT mutations are common in testicular seminomas. Am. J. Pathol.164, 305–313 (2004).
   PubMed Web of Science ®Google Scholar
• Rapley EA, Hockley S, Warren W et al. Somatic mutations of KIT in familial testicular germ cell tumours. Br. J. Cancer90, 2397–2401 (2004).
   PubMed Web of Science ®Google Scholar
• McIntyre A, Summersgill B, Grygalewicz B et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res.65, 8085–8089 (2005).
   PubMed Web of Science ®Google Scholar
• Coffey J, Linger R, Pugh J et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer47, 34–42 (2008).
   PubMed Web of Science ®Google Scholar
• Biermann K, Göke F, Nettersheim D et al. c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma. J. Pathol.213, 311–318 (2007).
   PubMed Web of Science ®Google Scholar
• Forbes S, Clements J, Dawson E et al. COSMIC 2005. Br. J. Cancer94, 318–322 (2006).
   PubMed Web of Science ®Google Scholar
• Rajpert-De Meyts E, Skakkebaek NE. Expression of the c-kit protein product in carcinoma-in situ and invasive testicular germ cell tumours. Int. J. Androl.12, 85–92 (1994).
   Google Scholar
• Strohmeyer T, Reese D, Press M, Ackermann R, Hartmann M, Slamon D. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J. Urol.153, 511–515 (1995).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Kuczyk MA, Dunn T et al. Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours. J. Cancer Res. Clin. Oncol.122, 301–306 (1996).
   PubMed Web of Science ®Google Scholar
• Looijenga LHJ, de Leeuw H, van Oorschot M et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res.63, 7674–7678 (2003).
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumours expressing KIT. Am. J. Clin. Oncol.29, 12–13 (2006).
   PubMed Web of Science ®Google Scholar
• Voorhoeve PM, Le Sage C, Schrier M et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell124, 1169–1181 (2006).
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell116, 281–297 (2004).
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer6, 857–866 (2006).
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet.3, 415–428 (2002).
   PubMed Web of Science ®Google Scholar
• Smiraglia DJ, Szymanska J, Kraggerud SM, Lothe RA, Peltomaki P, Plass C. Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene21, 3909–3916 (2002).
   PubMed Web of Science ®Google Scholar
• Koul S, Houldsworth J, Mansukhani MM et al. Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol. Cancer1, 8 (2002).
   PubMedGoogle Scholar
• Smith-Sørensen B, Lind GE, Skotheim RI et al. Frequent promoter hypermethylation of the O6-mMethylguanine-DNA methyltransferase (MGMT) gene in testicular cancer. Oncogene21, 8878–8887 (2002).
   PubMedGoogle Scholar
• Honorio S, Agathanggelou A, Wernet N, Rothe N, Maher ER, Latif F. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma germ cell tumours. Oncogene22, 461–466 (2003).
   PubMedGoogle Scholar
• Lind GE, Skotheim RI, Fraga MF, Abeler VM, Esteller M, Lothe RA. Novel epigenetically deregulated genes in testicular cancer include homeobox genes and SCGB3A1 (HIN-1). J. Pathol.210, 441–449 (2006).
   PubMed Web of Science ®Google Scholar
• Almstrup K, Hoei-Hansen CE, Nielsen JE et al. Genome-wide gene expression profiling of testicular carcinoma in situ progression into overt tumours. Br. J. Cancer92, 1934–1941 (2005).
   PubMedGoogle Scholar
• Port M, Schmelz HU, Stockinger M et al. Gene expression profiling in seminoma and nonseminoma. J. Clin. Oncol.23, 58–69 (2005).
   PubMedGoogle Scholar
• Okada K, Katagiri T, Tsunoda T et al. Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int. J. Oncol.23, 1615–1635 (2003).
   PubMedGoogle Scholar
• Korkola JE, Houldsworth J, Dobrzynski D et al. Gene expression-based classification of nonseminomatous male germ cell tumors. Oncogene24, 5101–5107 (2005).
   PubMedGoogle Scholar
• Juric D, Sale S, Hromas RA et al. Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc. Natl Acad. Sci. USA102, 17763–17768 (2005).
   PubMedGoogle Scholar
• Hofer MD, Browne TJ, He L, Skotheim RI, Lothe RA, Rubin MA. Identification of two molecular groups of seminomas by using expression and tissue microarrays. Clin. Cancer Res.11, 5722–5729 (2005).
   PubMedGoogle Scholar
• Sugimura J, Foster RS, Cummings OW et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin. Cancer Res.10, 2368–2378 (2004).
   PubMedGoogle Scholar
• Korkola J, Houldsworth J, Feldman DR et al. Outcome prediction in adult male germ cell tumor patients through expression profiling. J. Clin. Oncol.20(20 Suppl.), (2008) (Abstract 5084).
   Google Scholar
• Gillis AJ, Stoop HJ, Hermus R et al. High-throughput microRNAome analysis in human germ cell tumours. J. Pathol.213, 319–328 (2006).
   Google Scholar
• Aladjem MI, Spike BT, Rodewald LW et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damge. Curr. Biol.8, 145–155 (1998).
   PubMed Web of Science ®Google Scholar
• Hong Y, Stambrook PJ. Restoration of an absent G1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc. Natl Acad. Sci. USA101, 14443–14448 (2004).
   PubMed Web of Science ®Google Scholar
• Oosterhuis JW, Andrews PW, Knowles BB, Damjanov I. Effects of cis-platinum on embryonal cancer cell lines in vitro. Int. J. Cancer34, 133–139 (1984).
   PubMedGoogle Scholar
• Walker MC, Parris CN, Masters JR. Differential sensitivities to chemotherapeutic drugs between testicular and bladder cancer cells. J. Natl Cancer Inst.79, 213–216 (1987).
   PubMedGoogle Scholar
• Fry AM, Chresta CM, Davies SM et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res.51, 6592–6595 (1991).
   PubMed Web of Science ®Google Scholar
• Masters JR, Osborne EJ, Walker MC, Parris CN. Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs. Int. J. Cancer53, 340–346 (1993).
   PubMedGoogle Scholar
• Parris CN, Arlett CF, Lehmann AR, Green MH, Masters JR. Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med.53, 599–608 (1988).
   PubMedGoogle Scholar
• Masters JR, Köberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat. Rev. Cancer3, 517–525 (2003).
   PubMed Web of Science ®Google Scholar
• Kersemaekers AM, Mayer F, Molier M et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J. Clin. Oncol.20, 1551–1561 (2002).
   PubMed Web of Science ®Google Scholar
• Rogel A, Popliker M, Webb CG, Oren M. p53 cellular tumor antigen. analysis of mRNA levels in normal adult tisses, embryos, and tumors. Mol. Cell Biol.5, 2851–2855 (1985).
   PubMed Web of Science ®Google Scholar
• Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res.56, 1834–1841 (1996).
   PubMedGoogle Scholar
• Arriola EL, Rodriguez-Lopez AM, Hickman JA, Chresta CM. Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitises human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene18, 1457–1464 (1998).
   Google Scholar
• Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br. J. Cancer77, 1562–1567 (1998).
   PubMedGoogle Scholar
• Mayer F, Stoop H, Scheffer GL et al. Molecular determinants of treatment response in human germ cell tumors. Clin. Cancer Res.9, 767–773 (2003).
   PubMedGoogle Scholar
• Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry24, 707–713 (1985).
   PubMed Web of Science ®Google Scholar
• Zamble DB, Mu D, Reardon JT, Sancar A, Lippard SJ. Repair of cisplatin–DNA adducts by the mammalian excision nuclease. Biochemistry35, 10004–10013 (1996)
   PubMed Web of Science ®Google Scholar
• Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int. J. Cancer70, 551–555 (1997).
   PubMedGoogle Scholar
• Bedford P, Fichtinger-Schepman AM, Shellard SA, Walker MC, Masters JR, Hill BT. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res.48, 3019–3024 (1988).
   PubMed Web of Science ®Google Scholar
• Köberle B, Payne J, Grimaldi KA, Hartley JA, Masters JR. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem. Pharmacol.52, 1729–1734 (1996).
   PubMedGoogle Scholar
• Köberle B, Masters JR, Hartley JA, Wood RD. Defective repair of ?cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol.9, 273–276 (1999).
   PubMed Web of Science ®Google Scholar
• Welsh C, Day R, McGurk C, Masters JR, Wood RD, Köberle B. Reduced levels of XPA, ERRC1 and XPF DNA repair proteins in testis tumor cell lines. Int. J. Cancer110, 352–361 (2004).
   PubMed Web of Science ®Google Scholar
• Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ. Basis for the recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature399, 708–712 (1999).
   PubMed Web of Science ®Google Scholar
• Billings PC, Engelsberg BN, Hughes EN. Proteins binding to cisplatin-damaged DNA in human cell lines. Cancer Invest.12, 597–604 (1994).
   PubMed Web of Science ®Google Scholar
• Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl Acad. Sci. USA91, 10394–10398 (1994).
   PubMed Web of Science ®Google Scholar
• Zamble DB, Mikata Y, Eng CE, Sandman KE, Lippard SJ. Testis-specific HMG-domain protein alters the response of cells to cisplatin. J. Inorg. Biochem.91, 451–462 (2002).
   PubMed Web of Science ®Google Scholar
• Ohndorf UM, Whitehead JP, Raju NL, Lippard SJ. Binding to tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. Biochemistry36, 14807–14815 (1997).
   PubMedGoogle Scholar
• Trimer EE, Zamble DB, Lippard SJ, Essigmann JM. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry37, 352–362 (1998).
   PubMedGoogle Scholar
• Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol.53, 13–23 (2005).
   PubMed Web of Science ®Google Scholar
• Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev.26, 71–83 (2007).
   PubMed Web of Science ®Google Scholar
• Song IS, Savaraj N, Siddik ZH et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol. Cancer Ther.3, 1543–1549 (2004).
   PubMed Web of Science ®Google Scholar
• Komatsu M, Sumizawa T, Mutoh M et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res.60, 1312–1316 (2000).
   PubMed Web of Science ®Google Scholar
• Samimi G, Safaei R, Katano K et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res.10, 4661–4669 (2004).
   PubMed Web of Science ®Google Scholar
• Katano K, Safaei R, Samimi G, Holzer A, Rochdi M, Howell SB. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol. Pharmacol.64, 466–473 (2003).
   PubMedGoogle Scholar
• Nakayama K, Kanzaki A, Terada K et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients reeiving cisplatin-based chemotherapy. Clin. Cancer Res.10, 2804–2811 (2004).
   PubMed Web of Science ®Google Scholar
• Ohbu M, Ogawa K, Konno S et al. Copper-transporting P-type adenosine triphosphate (ATP7B) is expressed in human gastric carcinoma. Cancer Lett.189, 33–38 (2003).
   PubMedGoogle Scholar
• Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts D, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin. Cancer Res.9, 5853–5859 (2003).
   PubMed Web of Science ®Google Scholar
• Zurita AJ, Diestra JE, Condom E et al. Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br. J. Cancer88, 879–886 (2003).
   PubMed Web of Science ®Google Scholar
• Masters JR, Thomas R, Hall AG et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur. J. Cancer32A, 1248–1253 (1996).
   PubMed Web of Science ®Google Scholar
• Koropatnick J, Kloth DM, Kadhim S, Chin JL, Cherian MG. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line. J. Pharmacol. Exp. Ther.275, 1681–1687 (1995).
   PubMedGoogle Scholar
• Meijer C, Timmer A, De Vries EG et al. Role of metallothionein in cisplatin sensitivity of germ cell tumours. Int. J. Cancer85, 777–781 (2000).
   PubMed Web of Science ®Google Scholar
• Fink D, Nebel S, Aebi S et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res.56, 4881–4889 (1990).
   Google Scholar
• Mayer F, Gillis AJ, Dinjens W et al. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res.62, 2758–2760 (2002).
   PubMedGoogle Scholar
• Aebi S, Kurdi-Haidar B, Gordon R et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res.56, 3087–3090 (1996).
   PubMed Web of Science ®Google Scholar
• Fink D, Zheng H, Nebel S et al.In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res.57, 1841–1845 (1997).
   PubMed Web of Science ®Google Scholar
• Olasz J, Mándoky L, Géczi L, Bodrogi I, Csuka O, Bak O. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumours. Anticancer Res.25, 4319–4324 (2005).
   PubMed Web of Science ®Google Scholar
• Velasco A, Riquelme E, Schultz M et al. Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol. Ther.3, 1152–1158 (2004).
   PubMed Web of Science ®Google Scholar
• Velasco A, Corvalan A, Wistuba II et al. Mismatch repair expression in testicular cancer predicts recurrence and survival. Int. J. Cancer122, 1774–1777 (2008).
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Xiao H, Murty VV et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene16, 2345–2349 (1998).
   PubMed Web of Science ®Google Scholar
• Burger H, Nooter K, Boersma AW et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int. J. Cancer81, 620–628 (1999).
   PubMed Web of Science ®Google Scholar
• Spierings DC, de Vries EG, Vellenga E, de Jong S. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumour cell line. Cell Death Differ.10, 808–822 (2003).
   PubMed Web of Science ®Google Scholar
• Schweyer S, Soruri A, Meschter O et al. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br. J. Cancer91, 589–598 (2004).
   PubMed Web of Science ®Google Scholar
• Mueller T, Vogt W, Simon H et al. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res.63, 513–521 (2003).
   PubMed Web of Science ®Google Scholar
• Rao PH, Houldsworth J, Palanisamy N et al. Chromosomal amplification is associated with cisplatin resistance of human germ cell tumors. Cancer Res.58, 4260–4263 (1998).
   PubMedGoogle Scholar
• Wilson C, Yang J, Streffod JC et al. Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines. Genes Chromosomes Cancer43, 211–216 (2005).
   PubMedGoogle Scholar
• Duale N, Lindeman B, Komada M et al. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Mol. Cancer6, 53 (2007).
   PubMedGoogle Scholar